Melbourne Dental School, Faculty of Medicine Dentistry and Health Science, The University of Melbourne, Melbourne, VIC, Australia.
Regional HPV Labnet Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Melbourne, VIC, Australia.
J Oral Pathol Med. 2018 Jan;47(1):18-24. doi: 10.1111/jop.12649. Epub 2017 Oct 30.
The aim of this study was to identify the presence and frequency of human papillomavirus (HPV) nucleic acid in p16-positive oral squamous cell carcinomas (OSCCs), to assess whether the virus was transcriptionally active and to assess the utility of p16 overexpression as a surrogate marker for HPV in OSCC.
Forty-six OSCC patients treated between 2007 and 2011 with available formalin-fixed paraffin-embedded (FFPE) specimens were included. Twenty-three patients were positive for p16 by immunohistochemistry (IHC) and these were matched with 23 patients with p16-negative tumours. Laser capture microdissection of the FFPE OSCC tissues was undertaken to isolate invasive tumour tissue. DNA was extracted and tested for high-risk HPV types using a PCR-ELISA method based on the L1 SPF10 consensus primers, and a real-time PCR method targeting HPV-16 and HPV-18 E6 region. Genotyping of HPV-positive cases was performed using a reverse line blot hybridization assay (Inno-LiPA). RNAScope (a chromogenic RNA in situ hybridization assay) was utilized to detect E6/E7 mRNA of known high-risk HPV types for detection of transcriptionally active virus.
HPV DNA was found in 3 OSCC cases, all of which were p16 IHC-positive. Two cases were genotyped as HPV-16 and one as HPV-33. Only one of the HPV-16 cases was confirmed to harbour transcriptionally active virus via HPV RNA ISH.
We have shown that the presence of transcriptionally active HPV rarely occurs in OSCC and that p16 is not an appropriate surrogate marker for HPV in OSCC cases. We propose that non-viral mechanisms are responsible for the majority of IHC p16 overexpression in OSCC.
本研究旨在确定 p16 阳性口腔鳞状细胞癌(OSCC)中是否存在人乳头瘤病毒(HPV)核酸及其频率,评估病毒是否具有转录活性,并评估 p16 过表达作为 OSCC 中 HPV 的替代标志物的效用。
纳入了 2007 年至 2011 年间接受治疗且有可用福尔马林固定石蜡包埋(FFPE)标本的 46 例 OSCC 患者。23 例患者的免疫组化(IHC)结果为 p16 阳性,与 23 例 p16 阴性肿瘤患者相匹配。对 FFPE OSCC 组织进行激光捕获微切割以分离侵袭性肿瘤组织。提取 DNA 并使用基于 L1 SPF10 共识引物的 PCR-ELISA 方法以及针对 HPV-16 和 HPV-18 E6 区的实时 PCR 方法检测高危 HPV 型。使用反向线杂交分析(Inno-LiPA)对 HPV 阳性病例进行基因分型。使用 RNAscope(一种显色 RNA 原位杂交检测)检测已知高危 HPV 型的 E6/E7 mRNA,以检测转录活性病毒。
在 3 例 OSCC 病例中发现 HPV DNA,所有这些病例的 IHC 均为 p16 阳性。2 例为 HPV-16 型,1 例为 HPV-33 型。仅 HPV-16 病例中的 1 例通过 HPV RNA ISH 证实存在转录活性病毒。
我们表明,转录活性 HPV 在 OSCC 中很少发生,并且 p16 不是 OSCC 病例中 HPV 的合适替代标志物。我们提出,非病毒机制负责大多数 OSCC 中 IHC p16 过表达。